Jump to contents

Researcher Information

last modified:2024/03/12

Professor Tsutomu Shimada

Mail

Faculty, Affiliation

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences Hospital Pharmacy

College and School Educational Field


Laboratory

Department of Clinical Pharmacokinetics TEL:076-265-2046 FAX:076-234-4280

Academic Background

Career

Faculty of Pharmaceutical Sciences, Kanazawa University(1999/04/01-2002/03/31)
Kanazawa University Graduate School Natural Science and Technology Master program(2002/04/01-2004/03/31)
Kanazawa University Graduate School Natural Science and Technology Doctoral program (2002/04/01-2005/03/31)
Musashino University Research institute of Pharmaceutical Sci Research associate(2005/04/01-2007/04/30)
Musashino University Research institute of Pharmaceutical Sci Assistant Professor(2007/05/01-2010/03/31)
Musashino University Research institute of Pharmaceutical Sci Lecturer(2010/04/01-2012/03/31)
Musashino University Research institute of Pharmaceutical Sci Visiting Researcher(2012/04/01-2014/06/30)
TOKIWA Phytochemical Co., Ltd. R&D department  Advisor(2012/04/01-2012/06/30)
Alfred I. duPont Hospital for Children Biomedical Research Research Fellow(2012/07/25-2014/06/30)
University Hospital Kanazawa University Department of Hospital Pharmacy Associate Professor(2014/07/01-)

Year & Month of Birth

Academic Society

Pharmaceutical Society of Japan
Medical and Pharmaceutical Society for WAKAN-YAKU
The Japanese Society of Pharmaceutical Health Care and Sciences



Japanese Society for Parenteral and Enteral Nutrition



Award

○Best Poster Presenter(2022/02/13)
○Best Poster Presenter(2022/02/13)
○Best Poster Presenter(2022/02/13)
○Best Poster Presenter(2022/02/13)
○Best Poster Presenter(2022/02/13)
○Best Poster Presenter(2022/02/13)
○Best Poster Presenter(2022/02/13)
○Best Poster Presenter(2022/02/13)
○Best Poster Presenter(2022/02/13)

Specialities

Medical pharmacy

Speciality Keywords

Clinical Pharmacokinetics, Phytomedicine

Research Themes

Books

  •  Tomatsu S, Shimada T, Patel P, Mason RW, Mikami T, Kitagawa H, Akama T, Montano AM and Orii T Sulfated Polysaccharides Editor Gama M, Nader HB, Rocha H, .  NOVA SCIENCE PUBLISHERS, INC NY 2015

Papers

  •  Establishment of Glycosaminoglycan Assays for Mucopolysaccharidoses  Tomatsu S, Shimada T, Mason R, Montaño A, Kelly J, LaMarr W, Kubaski F, Giugliani R, Guha A, Yasuda E, Mackenzie W, Yamaguchi S, Suzuki Y, Orii T metabolites 4 3 655-79 2014/08
  •  Novel heparan sulfate assay by using automated high-throughput mass spectrometry: Application to monitoring and screening for mucopolysaccharidoses. Shimada T, Kelly J, LaMarr WA, van Vlies N, Yasuda E, Mason RW, Mackenzie W, Kubaski F, Giugliani R, Chinen Y, Yamaguchi S, Suzuki Y, Orii KE, Fukao T, Orii T, Tomatsu S. Mol Genet Metab 113 92-99 2014/05
  •  Chondroitin 6-Sulfate as a Novel Biomarker for Mucopolysaccharidosis IVA and VII. Shimada T, Tomatsu S, Yasuda E, Mason RW, Mackenzie WG, Shibata Y, Kubaski F, Giugliani R, Yamaguchi S, Suzuki Y, Orii K, Orii T. JIMD Rep 16 15-24 2014/05
  •  Salacia reticulata has therapeutic effects on obesity. Shimada T, Nakayama Y, Harasawa Y, Matsui H, Kobayashi H, Sai Y, Miyamoto KI, Tomatsu S, Aburada M. J Nat Med 68 4 668-676 2014/05
  •  Suppression of adipocyte hypertrophy by polymethoxyflavonoids isolated from Kaempferia parviflora. Okabe Y, Shimada T, Horikawa T, Kinoshita K, Koyama K, Ichinose K, Aburada M, Takahashi K. Phytomedicine 21 6 800-6 2014/05

show all

  •  Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: Early treatment rescues bone lesions? Tomatsu S,Montaño AM,Oikawa H,Dung VC,Hashimoto A,Oguma T,Gutiérrez ML,Takahashi T,Shimada T,Orii T,Sly WS Mol Genet Metab 2014/04
  •  Impact of Enzyme Replacement Therapy and Hematopoietic Stem Cell Therapy on Growth in Patients with Hunter Syndrome. Patel P,Suzuki Y,Tanaka A,Yabe H,Kato S,Shimada T,Mason RW,Orii KE,Fukao T,Orii T,Tomatsu S Mol Genet Metab Rep 1 184-196 2014/04
  •  Pharmacokinetics of 6-shogaol, a pungent ingredient of Zingiberis Rhizoma, and the anti-inflammatory activity of its metabolite, 6-paradol Daisuke Tokuhara, Tsutomu Shimada, Akitoshi Asami, Akiko Takahashi, Hiroko Kobayashi, Hiroshi Saimaru, Masaki Aburada Journal of Traditional Medicine 30 5 199-205 2013/10
  •  Enzyme replacement therapy on hypophosphatasia mouse model. Oikawa H, Tomatsu S, Haupt B, Montaño AM, Shimada T, Sly WS. J Inherit Metab Dis 37 2 309-17 2014/03
  •  Assay for Glycosaminoglycans by Tandem Mass Spectrometry and its Applications. Tomatsu S,Shimada T,Mason RW,Kelly J,LaMarr WA,Yasuda E,Shibata Y,Futatsumori H,Montaño AM,Yamaguchi S,Suzuki Y,Orii T J Anal Bioanal Tech 2014 Suppl 2 006 2014/03
  •  A dietary restriction influences the progression but not the initiation of MSG-Induced nonalcoholic steatohepatitis. Fujimoto M, Tsuneyama K, Nakanishi Y, Salunga TL, Nomoto K, Sasaki Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Shimada Y, Gershwin ME, Selmi C. J Med Food 17 3 374-83 2014/03
  •  Growth charts for patients with Hunter syndrome. Patel P,Suzuki Y,Maeda M,Yasuda E,Shimada T,Orii KE,Orii T,Tomatsu S Mol Genet Metab Rep 1 5-18 2014/01
  •  Newborn screening and diagnosis of mucopolysaccharidoses. Tomatsu S, Fujii T, Fukushi M, Oguma T, Shimada T, Maeda M, Kida K, Shibata Y, Futatsumori H, Montaño AM, Mason RW, Yamaguchi S, Suzuki Y, Orii T. Mol Genet Metab 110 1-2 42-53 2013/09
  •  Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder. Yasuda E, Fushimi K, Suzuki Y, Shimizu K, Takami T, Zustin J, Patel P, Ruhnke K, Shimada T, Boyce B, Kokas T, Barone C, Theroux M, Mackenzie W, Nagel B, Ryerse JS, Orii KE, Iida H, Orii T, Tomatsu S. Mol Genet Metab 109 3 301-11 2013/07
  •  Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome. Nishida T, Tsuneyama K, Fujimoto M, Nomoto K, Hayashi S, Miwa S, Nakajima T, Nakanishi Y, Sasaki Y, Suzuki W, Iizuka S, Nagata M, Shimada T, Aburada M, Shimada Y, Imura J. Lab Invest 93 2 230-41 2013/02
  •  Aging-like skin changes in metabolic syndrome model mice are mediated by mineralocorticoid receptor signaling. Nagase T, Akase T, Sanada H, Minematsu T, Ibuki A, Huang L, Asada M, Yoshimura K, Nagase M, Shimada T, Aburada M, Nakagami G, Sugama J. Aging Cell 12 1 50-7 2013/02
  •  Advances in therapies of Mucopolysaccharidosis IVA (Morquio A Syndrome)  Tomatsu S, Alméciga-Díaz CJ, Montaño AM, Barrera LA, Shimada T, Yasuda E, Patel P, Mackenzie WG, Mason R, Corao D, Suzuki Y, Orii KE, Orii T Expert Opinion on Orphan Drugs 1 10 805-18 2013/01
  •  Tetrandrine prevents bone loss in sciatic-neurectomized mice and inhibits receptor activator of nuclear factor κB ligand-induced osteoclast differentiation. Biol Pharm Bull. 2012;35(10):1765-74. Takahashi T, Tonami Y, Tachibana M, Nomura M, Shimada T, Aburada M, Kobayashi S. Biol Pharm Bull 35 10 1765-74 2012/10
  •  Puerariae flos alleviates metabolic diseases in Western diet-loaded, spontaneously obese type 2 diabetic model mice. Kubo K, Shimada T, Onishi R, Tsubata M, Kamiya T, Nagamine R, Iizuka S, Sai Y, Amagaya S, Aburada M, Miyamoto K. J Nat Med 66 4 622-30 2012/10
  •  Preventive effect of Terminalia bellirica on obesity and metabolic disorders in spontaneously obese type 2 diabetic model mice. Makihara H, Shimada T, Machida E, Oota M, Nagamine R, Tsubata M, Kinoshita K, Takahashi K, Aburada M. J Nat Med 66 3 459-67 2012/07
  •  Disposition kinetics of taxanes in peritoneal dissemination.  Miyamoto K, Shimada T, Sawamoto K, Sai Y, Yonemura Y. Gastroenterol Res Pract 2012 doi:10.1155/2012/963 2012/05
  •  Polymethoxyflavonoids from Kaempferia parviflora induce adipogenesis on 3T3-L1 preadipocytes by regulating transcription factors at an early stage of differentiation. Biol Pharm Bull. 2012;35(5):686-92. Horikawa T, Shimada T, Okabe Y, Kinoshita K, Koyama K, Miyamoto K, Ichinose K, Takahashi K, Aburada M. Biol Pharm Bull 35 5 686-92 2012/05
  •  The crude extract from puerariae flower exerts antiobesity and antifatty liver effects in high-fat diet-induced obese mice. Kamiya T, Sameshima-Kamiya M, Nagamine R, Tsubata M, Ikeguchi M, Takagaki K, Shimada T, Aburada M. Evid Based Complement Alternat Med doi: 10.1155/2012/27 2012/05
  •  Aging-like skin changes induced by ultraviolet irradiation in an animal model of metabolic syndrome. Akase T, Nagase T, Huang L, Ibuki A, Minematsu T, Nakagami G, Ohta Y, Shimada T, Aburada M, Sugama J, Sanada H. Biol Res Nurs 14 2 180-7 2012/04
  •  The molecular mechanisms of the hepatoprotective effect of gomisin A against oxidative stress and inflammatory response in rats with carbon tetrachloride-induced acute liver injury. Biol Pharm Bull. 2012;35(2):171-7. Teraoka R, Shimada T, Aburada M. Biol Pharm Bull 35 2 171-7 2012/02
  •  Preventive effect of Kaempferia parviflora ethyl acetate extract and its major components polymethoxyflavonoid on metabolic diseases. Shimada T, Horikawa T, Ikeya Y, Matsuo H, Kinoshita K, Taguchi T, Ichinose K, Takahashi K, Aburada M. Fitoterapia 82 8 1272-8 2011/12
  •  Flavangenol (pine bark extract) and its major component procyanidin B1 enhance fatty acid oxidation in fat-loaded models. Shimada T,Tokuhara D,Tsubata M,Kamiya T,Kamiya-Sameshima M,Nagamine R,Takagaki K,Sai Y,Miyamoto K,Aburada M EUROPEAN JOURNAL OF PHARMACOLOGY 677 1-3 147-53 2011/12
  •  Skin fragility in obese diabetic mice: possible involvement of elevated oxidative stress and upregulation of matrix metalloproteinases. Ibuki A,Akase T,Nagase T,Minematsu T,Nakagami G,Horii M,Sagara H,Komeda T,Kobayashi M,Shimada T,Aburada M,Yoshimura K,Sugama J,Sanada H Exp Dermatol 21 3 178-83 2011/11
  •  Advantages and disadvantages of hyperbaric oxygen treatment in mice with obesity hyperlipidemia and steatohepatitis. ScientificWorldJournal. 2011;11:2124-35. Tsuneyama K, Chen YC, Fujimoto M, Sasaki Y, Suzuki W, Shimada T, Iizuka S, Nagata M, Aburada M, Chen SY. ScientificWorldJournal 11 2124-35 2011/10
  •  Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells. Biol Pharm Bull. 2011;34(10):1613-8. Kojima K, Shimada T, Nagareda Y, Watanabe M, Ishizaki J, Sai Y, Miyamoto K, Aburada M. Biol Pharm Bull 34 10 1613-8 2011/07
  •  Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. Eur J Pharmacol. 2011 Jul 15;662(1-3):1-8. Sasaki Y, Shimada T, Iizuka S, Suzuki W, Makihara H, Teraoka R, Tsuneyama K, Hokao R, Aburada M. Eur J Pharmacol 662 1-3 1-8 2011/07
  •  Salacia reticulata inhibits differentiation of 3T3-L1 adipocytes. Shimada T, Nagai E, Harasawa Y, Watanabe M, Negishi K, Akase T, Sai Y, Miyamoto K, Aburada M. J Ethnopharmacol 136 1 67-74 2011/06
  •  Preventive Effect of Boiogito on Metabolic Disorders in the TSOD Mouse, a Model of Spontaneous Obese Type II Diabetes Mellitus. Shimada T, Akase T, Kosugi M, Aburada M. Evid Based Complement Alternat Med doi: 10.1093/ecam/ne 2011/06
  •  Preventive Effects of Salacia reticulata on Obesity and Metabolic Disorders in TSOD Mice. Akase T, Shimada T, Harasawa Y, Akase T, Ikeya Y, Nagai E, Iizuka S, Nakagami G, Iizaka S, Sanada H, Aburada M. Evid Based Complement Alternat Med doi: 10.1093/ecam/ne 2011/06
  •  Preventive effect of pine bark extract (flavangenol) on metabolic disease in Western diet-loaded tsumura suzuki obese diabetes mice. Shimada T, Kosugi M, Tokuhara D, Tsubata M, Kamiya T, Sameshima M, Nagamine R, Takagaki K, Miyamoto K, Aburada M. Evid Based Complement Alternat Med  doi: 10.1093/ecam/n 2011/03
  •  Preventive effects of Salacia reticulata on non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH) in monosodium glutamate treated mice  Watanabe M, Shimada T, Iiduka S, Iida N, Kojima K, Ishizak J, Sai Y, Miyamoto K, Aburada M Journal of Traditional Medicines 28 2 73-82 2011/02
  •  Antiobesity effects of Kaempferia parviflora in spontaneously obese type II diabetic mice. J Nat Med. 2011 Jan;65(1):73-80. Akase T, Shimada T, Terabayashi S, Ikeya Y, Sanada H, Aburada M. J Nat Med 65 1 73-80 2011/01
  •  Metabolic disease prevention and suppression of fat accumulation by Salacia reticulata.  Shimada T, Nagai E, Harasawa Y, Akase T, Aburada T, Iizuka S, Miyamoto K, Aburada M. J Nat Med 64 3 266-74 2010/07
  •  Pharmacokinetics of [6]-shogaol, a pungent ingredient of Zingiber officinale Roscoe (Part I).  Asami A, Shimada T, Mizuhara Y, Asano T, Takeda S, Aburada T, Miyamoto K, Aburada M. J Nat Med. 64 3 281-7 2010/07
  •  A study of cardiovascular function in Tsumura Suzuki obese diabetes, a new model mouse of type 2 diabetes. Biol Pharm Bull. 2010;33(6):998-1003. Kawada T, Miyata S, Shimada T, Sanzen Y, Ito M, Hemmi C, Iizuka S, Suzuki W, Mihara K, Aburada M, Nakazawa M. Biol Pharm Bull 33 6 998-1003 2010/03
  •  Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice. Life Sci. 2009 Sep 23;85(13-14):490-8. Sasaki Y, Suzuki W, Shimada T, Iizuka S, Nakamura S, Nagata M, Fujimoto M, Tsuneyama K, Hokao R, Miyamoto K, Aburada M. LIFE SCIENCES 85 13-14 490-8 2009/09
  •  [The effect of theanine on oxygen-induced retinal neovascularization in the neonatal rat]. Hiramatsu R, Nakanishi-Ueda T, Takenaka Y, Ueda T, Tomoyasu S, Iketani Y, Shimada T, Aburada M, Yasuhara H, Koide R. Nihon Ganka Gakkai Zasshi 112 8 669-73 2008/08
  •  Preventive effects of Bofutsushosan on obesity and various metabolic disorders. Shimada T, Kudo T, Akase T, Aburada M. Biol Pharm Bull 31 7 1362-7 2008/07
  •  Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B. Ishizaki J, Ito S, Jin M, Shimada T, Ishigaki T, Harasawa Y, Yokogawa K, Takami A, Nakao S, Miyamoto K. Biopharm Drug Dispos. 29 4 195-203 2008/05
  •  Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. Nakanishi Y, Tsuneyama K, Fujimoto M, Salunga TL, Nomoto K, An JL, Takano Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Nakano M, Selmi C, Gershwin ME. J Autoimmun 30 1-2 42-50 2008/02
  •  Efficacy of Tokishakuyakusan on the anemia in the iron-deficient pregnant rats.  Akase T, Hihara E, Shimada T, Kojima K, Akase T, Tashiro S, Aburada M. Biol Pharm Bull 30 8 1523-8 2007/08
  •  Effects of green tea fractions on oxygen-induced retinal neovascularization in the neonatal rat. Saito Y,Hasebe-Takenaka Y,Ueda T,Nakanishi-Ueda T,Kosuge S,Aburada M,Shimada T,Ikeya Y,Onda H,Ogura H,Taguchi Y,Yasuhara H,Koide R J Clin Biochem Nutr 41 1 43-9 2007/07
  •  Inhibitory Effects of Tea Catechins on Lipid Peroxidation Induced by Rose Bengal and Blue Light Exposure in Porcine Retinal Homogenate Nakanishi-Ueda T, Taguchi Y, Ueda T, Yano S, Aburada M, Shimada T, Koide R, Yasuhara H The Showa University Journal of Medical Sciences 19 1 43-51 2007/01
  •  Involvement of alpha1-acid glycoprotein in inter-individual variation of disposition kinetics of ropivacaine following epidural infusion in off-pump coronary artery bypass grafting. Yokogawa K, Shimomura S, Ishizaki J, Shimada T, Fukuwa C, Kawada M, Tsubokawa T, Yamamoto K, Miyamoto K. J Pharm Pharmacol 59 1 67-73 2007/01
  •  Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats.  Khemawoot P, Yokogawa K, Shimada T, Miyamoto K. Biochem Pharmacol 73 1 155-62 2007/01
  •  Insulin resistance and low sympathetic nerve activity in the Tsumura Suzuki obese diabetic mouse: a new model of spontaneous type 2 diabetes mellitus and obesity. Takahashi A, Tabuchi M, Suzuki W, Iizuka S, Nagata M, Ikeya Y, Takeda S, Shimada T, Aburada M. Metabolism 55 12 1664-9 2006/12
  •  Preventive effects of Daisaikoto on metabolic disorders in spontaneous obese type II diabetes mice  Tsunakawa M, Shimada T, Suzuki W, Nagata M, Takeda S, Mizuno A, Kosugi M, Aburada M. Journal of Traditional Medicines 23 6 216-23 2006/11
  •  Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, Miyamoto K. Biochem Pharmacol 72 8 1042-50 2006/10
  •  Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Jin M,Shimada T,Yokogawa K,Nomura M,Kato Y,Tsuji A,Miyamoto K Int J Pharm 309 1-2 81-6 2006/02
  •  Effects of 1-benzylxanthines on cyclic AMP phosphodiesterase 4 isoenzyme. Suzuki H, Sawanishi H, Nomura M, Shimada T, Miyamoto K. Biol Pharm Bull. 29 1 131-4 2006/01
  •  Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine. Jin M,Shimada T,Shintani M,Yokogawa K,Nomura M,Miyamoto K Drug Metab Pharmacokinet 20 5 324-30 2005/10
  •  Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis IVA. 2014 Shimada T, Tomatsu S, Mason RW, Yasuda E, Mackenzie WG, Hossain J, Shibata Y, Montaño AM, Kubaski F, Giugliani R, Yamaguchi S, Suzuki Y, Orii KE, Fukao T, Orii T  J Inherit Metab Dis Reports 21 1-13 2015/02
  •  Cremophor EL releases cyclosporin A adsorbed on blood cells and blood vessels, and increases apparent plasma concentration of cyclosporin A. Jin M, Shimada T, Yokogawa K, Nomura M, Mizuhara Y, Furukawa H, Ishizaki J, Miyamoto K. Int J Pharm 293 1-2 137-44 2005/04
  •  Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. Shimada T, Nomura M, Yokogawa K, Endo Y, Sasaki T, Miyamoto K, Yonemura Y. J Pharm Pharmacol 57 2 177-81 2005/02
  •  Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2. Shimada T, Nakanishi T, Tajima H, Yamazaki M, Yokono R, Takabayashi M, Shimada T, Sawamoto K, Miyamoto K, Kitagawa H, Ohta T, Tamai I, Sai Y. J Pharm Sci.  104 9 3162-3169 2015/06
  •  Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer.  Yonemura Y1, Endou Y, Bando E, Kuno K, Kawamura T, Kimura M, Shimada T, Miyamoto K, Sasaki T, Sugarbaker PH. Cancer Lett. 210 2 189-96 2004/07
  •  Newborn screening and diagnosis of mucopolysaccharidoses: application of tandem mass spectrometry Tomatsu S, Kubaski F, Sawamoto K, Mason RW, Yasuda E, Shimada T, Montaño AM, Yamaguchi S, Suzuki Y, Orii T.  Nihon Masu Sukuriningu Gakkai Shi 2 65-76 2015/03
  •  Influence of cytarabine and cyclophosphamide on the disposition kinetics of cyclosporin A after bone marrow transplantation.  Shimada T, Aoki Y, Yokogawa K, Nomura M, Ishizaki J, Nishigami J, Miyamoto K. Transpl Int. 16 11 788-93 2003/11
  •  Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations.  Tomatsu S, Sawamoto K, Shimada T, Bober MB, Kubaski F, Yasuda E, Mason RW, Khan S, Alméciga-Díaz CJ, Barrera LA, Mackenzie WG, Orii T. Expert Opin Orphan Drugs. 3 11 1279-1290 2015/09
  •  Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K, Kaneko S, Kobayashi K, Miyamoto K. Transplantation 74 10 1 2002/11
  •  Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Yokogawa K, Shimada T, Higashi Y, Itoh Y, Masue T, Ishizaki J, Asahi M, Miyamoto K. Biochem Pharmacol. 63 4 777-83 2002/02
  •  Activity of daily living for Morquio A syndrome.  Yasuda E, Suzuki Y, Shimada T, Sawamoto K, Mackenzie WG, Theroux MC, Pizarro C, Xie L, Miller F, Rahman T, Kecskemethy HH, Nagao K, Morlet T, Shaffer TH, Chinen Y, Yabe H, Tanaka A, Shintaku H, Orii KE, Orii KO, Mason RW, Montaño AM, Fukao T, Orii T, Tomatsu S. Mol Genet Metab. 118 2 111-22 2016/06
  •  PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration. Akashita G, Hosaka Y, Noda T, Isoda K, Shimada T, Sawamoto K, Miyamoto K, Taniguchi T, Sai Y. J Pharm Health Care Sci. 1 31 2015/11
  •  Gallic Acid, the Active Ingredient of Terminalia bellirica, Enhances Adipocyte Differentiation and Adiponectin Secretion. Makihara H, Koike Y, Ohta M, Horiguchi-Babamoto E, Tsubata M, Kinoshita K, Akase T, Goshima Y, Aburada M, Shimada T Biol Pharm Bull 36 7 1137-43 2016
  •  Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients Ueda R, Yamamoto N, Hori Y, Yoshida K, Ohtsubo K, Terashima T, Shimada T, Sai Y J Pharm Health Care Sci 8 5 2022
  •  Limited Impact of Murine Placental MDR1 on Fetal Exposure of Certain Drugs Explained by Bypass Transfer Between Adjacent Syncytiotrophoblast Layers Fujita A, Noguchi S, Hamada R, Inoue S, Shimada T, Katakura S, Maruyama T, Sai Y, Nishimura T, Tomi M Pharm Res 2022
  •  Initial Serum C-reactive Protein Level as a Predictor of Increasing Serum Vancomycin Concentration During Treatment Isoda K, Nakade J, Suga Y, Fujita A, Shimada T, Sai Y Ther Drug Monit. 43 5 652-656 2021
  •  Effect of NOS Inhibitors and Anticoagulants on Nitric Oxide Production in a Tissue-factor Induced Rat DIC Model  Suga Y, Takahashi Y, Shimada T, Yamada S, Morishita E, Asakura H In Vivo. 35 4 1999-2004 2021
  •  Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma  Misaka K, Suga Y, Staub Y, Tsubata A, Shimada T, Sai Y, Matsushita R In Vivo 34 6 3459-3645 2020
  •  Administration of erlotinib in apple juice overcomes decreased absorption in a rat model of gastric acid suppression  Shimada T, Okano M, Yamada M, Ogawa Y, Ueda A, Nagake K, Yoshimichi Sai Drug Metab Pharmacokinet  35 6 534-538 2020
  •  Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer  Shimura Y, Suga Y, Itai S, Iwamoto H, Takezawa Y, Yaegashi H, Izumi K, Shimada T, Sai Y, Matsushita R, Mizokami A Anticancer Res 40 8 4291-4297 2020
  •  The active ingredients in the anti-obesity drugbofutsushosan in high-fat-diet-fed obese mice  Takahashi T, Hori K, Yoshida E, Ikeda-Matsuo Y, Shimada T, Nomura M, Kobayashi S Traditional & Kampo Medicine 2020
  •  Examination of Aggregate Formation upon Simultaneous Dissolution of Methacrylic Acid Copolymer LD Enteric Coating Agent, Pharmaceutical Additives, and Zwitterionic Ingredients  Nakagawa Y, Suzuki T, Suga Y, Shimada Y, Sai Y Biol. Pharm. Bull 43 682-687 2020
  •  Incidence and risk factors of neonatal hypoglycemia after ritodrine therapy in premature labor: a retrospective cohort study  Shimokawa S, Sakata A, Suga Y, Isoda K, Itai S, Nagase K, Shimada T, Sai Y. J Pharm Health Care Sci 5 7 2019/04/16
  •  Detailed assessment and risk factor analysis of corticosteroid-induced psychiatric disorders in pediatric, adolescent, and young adult patients undergoing induction or consolidation therapy for hematologic malignancy. Staub Y, Suga Y, Ikawa Y, Tsubouchi K, Hashimoto M, Kawagishi A, Shimada T, Sai Y, Nishimura K, Matsushita R. J Oncol Pharm Pract. 1078155219879992 2019/10/21
  •  Hatano rats are a suitable metabolic syndrome model for studying feeding behavior, blood pressure levels, and percent body fat Isobe A, Shimada T, Aburada M, Yanagisawa R, Sakawa T, Nakamura T, Himi T, Ohta R, Kawaguchi M J VET MED SCI 81 1 147-154 2019/01/25
  •  Palonosetron on Days 1 and 5 Versus Granisetron Daily (Days 1-5) in Germ Cell Tumour Therapy. Shimura Y, Izumi K, Itai S, Iwamoto H, Yaegashi H, Suga Y, Shimada T, Mizokami A, Sai Y. In vivo 33 2 643-647 2019/03/01
  •  Multiday corticosteroids in cancer chemotherapy delay the diagnosis of and antimicrobial administration for febrile neutropenia: a double-center retrospective study Uda H, Suga Y, Toriba E, Staub AY, Shimada T, Sai Y, Kawahara M, Matsusita R J Pharm Health Care Sci. 5 3 2019/02/04
  •  Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies Hashimoto S, Honda K, Fujita K, Miyachi Y, Isoda K, Misaka K, Suga Y, Kato S, Tsuchiya H, Kato Y, Okajima M, Taniguchi T, Shimada T, Sai Y. J Pharm Health Care Sci. 4 27 2018/11/12
  •  Incidence and Risk Factors of Cholinergic Syndromes Induced by FOLFIRINOX in Advanced Pancreatic  Itho T, Nakade J, Shimada T, Sai Y. Jpn J Pharm Health Care Sci. 44 8 403-410 2018/08
  •  Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy  Suga Y, Ikeda N, Maeda M, Staub AY, Shimada T, Yonezawa M, Kitade H, Katsura H, Okada M, Ishizaki J, Sai Y, Matsushita R. J Pharm Health Care Sci. 4 18 2018/08
  •  Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells. Hioki M, Shimada T, Yuan T, Nakanishi T, Tajima H, Yamazaki M, Yokono R, Takabayashi M, Sawamoto K, Akashita G, Miyamoto KI, Ohta T, Tamai I, Shimada T, Sai Y. Biopharm Drug Dispos. 39 5 256-263 2018/01
  •  Drug interaction between methotrexateand salazosulfapyridine in Japanesepatients with rheumatoid arthritis  Okada M, Fujii H, Suga Y, Morito S, Okada M, Nishigami J, Kawano M, Shimada T, Sai Y. Journal of Pharmaceutical Health Care and Sciences 3 7 2017/01
  •  Multiple Oral Dosing Pharmacokinetics of Standardized Extract of Centella asiatica ECa 233 and Its Inductive Effect on Efflux Transporters in Rats Anukunwithaya T, Tantisira MH, Shimada T, Sai Y, Khemawoot P Planta Medica International Open 4 2 e66-73 2017/08/28
  •  Effects of ethyl acetate extract of Kaempferia parviflora on brown adipose tissue  Kobayashi Y, Horiguchi-Babamoto E, Suzuki M, Makihara H, Tomozawa H, Tsubata M, Shimada T, Sugiyama K, Aburada M,  Journal of Natural Medicines  70 1 54-61  2016
  •  Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study Itai S, Suga Y, Hara Y, Izumi K, Maeda Y, Kitagawa Y, Ishizaki J, Shimada T, Mizokami A, Sai Y. Journal of Pharmaceutical Health Care and Sciences 3 3 2017/01
  •  Effect of Kaempferia parviflora extract on knee osteoarthritis. Kobayashi H, Suzuki R, Sato K, Ogami T, Tomozawa H, Tsubata M, Ichinose K, Aburada M, Ochiai W, Sugiyama K, Shimada T Journal of Natural Medicines 72 1 136-144 2018/07
  •  ランソプラゾールOD錠とレボフロキサシン錠同時懸濁時における凝集物生成の原因と対策 43 1 26-33 2017/01

Conference Presentations

  • Biphasic Hepatic Uptake of Gemcitabine Characterized by Contribution of ENT1 and ENT2(conference:19th North American ISSX Meeting and 29th JSSX Annual Meeting)(2014/10)
  • A longitudinal survey on urinary independence and prescription trends in post-stroke patients(conference:ACCP 2022)(2022/02/11)
  • Long-term administration of Elental® affects the pharmacokinetic parameters of oral tacrolimus in rats(conference:ACCP 2022)(2022/02/11)
  • The comparison of the MDR1 contribution to the drug distribution of the placental barrier and blood-brain barrier(2021/10/23)
  • To clarify mechanism of neonatal hypoglycemia by ritodrine(2021/10/23)

show all

  • The effect of long-term enteral nutrition on intestinal microbiota and pharmacokinetic factors(conference:2018 ACCP Global conference)(2018/11/21)
  • emcitabine Uptake System of Pancreatic Tumor is Mainly Contributed by Equilibrated Nucleoside Transporter 2(conference:2018 MDO/JSSX in Kanazawa)(2014/10/02)
  • Pharmacokinetics of fentanyl after dermal administration to arthritis model rats(conference:WCP 2018)(2018/07/03)

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

○Pharmacokinetics variation on various disorders

Grant-in-Aid for Scientific Research

○「薬物動態変動要因としての栄養組成および腸内細菌叢環境の関与」(2015-2016) 
○「「Kaempferia parvifloraの代謝疾患予防効果および作用機序の解明」」(2009-2011) 
○「「肥満児の薬物動態変動による医薬品副作用の回避戦略」、」(2015-2018) 
○「「がん薬物療法における血管痛発現機序の解明および新規予防法の開発」」(2016-2019) 
○「「メタボリックシンドローム(代謝症候群)に対して有効な伝統生薬の探索研究」」(2007-2008) 
○2022「病態背景が経皮吸収型製剤の経皮アベイラビリティにおよぼす影響」(2020-2022) 
○「加齢による薬物体内動態の個人間変動予測の新機軸」(2019-2022) 
○「室内ダスト中の化学物質暴露による腸内細菌叢の変化は生体高次機能をかく乱し得るのか」(2017-2019) 
○「careとcureを融合した看護薬剤学モデルの開発」(2017-2019) 
○「環境中化学物質暴露による腸内細菌叢バランスの破綻が薬物投与設計に与える影響」(2017-2019) 

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

○Clinical Pharmacology(2021)
○Pharmacy Practice 2(2021)
○Basic and Clinical Pharmacology(2021)
○Clinical Pharmacy Practice(2021)
○Pharmacy Practice 1(2021)
○Safety Management for Drug Therapy(2021)
○Pharmacy Practice 3(2021)
○Clinical Pharmacology(2020)
○Pharmacy Practice 3(2020)
○Pharmacy Practice 1(2020)
○Pharmacy Practice 2(2020)
○Clinical Pharmacy Practice(2020)
○Pharmacy Practice 4(2020)
○Safety Management for Drug Therapy(2020)
○Basic and Clinical Pharmacology(2020)
○Hospital Pharmacy Practice 2(2017)
○Hospital Pharmacy Practice 1(2017)
○Safety Management for Drug Therapy(2017)
○Safety Management for Drug Therapy(2016)
○Hospital Pharmacy Practice 1(2016)
○Hospital Pharmacy Practice 2(2016)

Classes (Graduate Schools)

○Medicinal Informatics(2021)
○Medicinal Informatics(2021)
○Medicinal Informatics(2020)
○Medicinal Informatics(2020)
○The Human Body in Health and Disease Curriculum 3(2020)
○Medicinal Informatics(2017)
○Medicinal Informatics(2017)
○Medicinal Informatics(2016)
○Medicinal Informatics(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top